Insider Buying: NextCure (NASDAQ:NXTC) Major Shareholder Purchases $38,990.00 in Stock

NextCure, Inc. (NASDAQ:NXTC) major shareholder Adar1 Capital Management, Llc purchased 7,798 shares of the firm’s stock in a transaction that occurred on Monday, July 27th. The stock was bought at an average price of $5.00 per share, for a total transaction of $38,990.00. Following the purchase, the insider owned 383,456 shares in the company, valued at $1,917,280. The trade was a 2.08% increase in their position. The purchase was disclosed in a document filed with the SEC, which is accessible through this link. Major shareholders that own at least 10% of a company’s shares are required to disclose their transactions with the SEC.

Adar1 Capital Management, Llc also recently made the following trade(s):

• On Wednesday, July 29th, Adar1 Capital Management, Llc purchased 3,410 shares of NextCure stock. The stock was bought at an average cost of $5.00 per share, for a total transaction of $17,050.00.
• On Tuesday, July 28th, Adar1 Capital Management, Llc acquired 6,400 shares of NextCure stock. The shares were bought at an average price of $4.95 per share, with a total value of $31,680.00.

NextCure Trading Down 7.4%

Shares of NASDAQ:NXTC traded down $0.40 during trading on Wednesday, reaching $5.02. 355,456 shares of the stock were exchanged, compared to its average volume of 939,730. NextCure, Inc. has a 12 month low of $1.55 and a 12 month high of $15.74. The stock has a 50-day moving average price of $3.76 and a 200-day moving average price of $8.83. The firm has a market cap of $18.12 million, a PE ratio of -0.29 and a beta of 1.42.

NextCure (NASDAQ:NXTC) last released its quarterly earnings results on Thursday, May 7th. The company reported ($1.87) earnings per share for the quarter, topping the consensus estimate of ($2.10) by $0.23. On average, sell-side analysts expect that NextCure, Inc. will post -7.89 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms recently commented on NXTC. Weiss Ratings lowered shares of NextCure from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, July 7th. Zacks Research upgraded shares of NextCure from a “strong sell” rating to a “hold” rating in a research report on Thursday, June 11th. HC Wainwright reiterated a “buy” rating and issued a $20.00 price target on shares of NextCure in a research report on Wednesday, July 15th. Finally, Wall Street Zen cut NextCure from a “hold” rating to a “sell” rating in a research note on Saturday, July 18th. Two analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $19.00.

Institutional Investors Weigh In On NextCure

Large investors have recently bought and sold shares of the company. Affinity Asset Advisors LLC increased its holdings in NextCure by 28.9% in the 4th quarter. Affinity Asset Advisors LLC now owns 247,294 shares of the company’s stock valued at $3,509,000 after buying an additional 55,412 shares during the period. Ikarian Capital LLC bought a new stake in shares of NextCure during the 4th quarter worth approximately $3,382,000. Squadron Capital Management LLC acquired a new stake in shares of NextCure during the 4th quarter worth approximately $3,363,000. Exome Asset Management LLC acquired a new stake in shares of NextCure during the 4th quarter worth approximately $2,341,000. Finally, AWM Investment Company Inc. bought a new position in NextCure in the fourth quarter valued at approximately $1,665,000. 42.65% of the stock is currently owned by institutional investors and hedge funds.

NextCure Company Profile

NextCure, Inc is a clinical‐stage biopharmaceutical company focused on the discovery and development of novel immune modulators for the treatment of cancer and inflammatory diseases. Leveraging its proprietary Therapeutic Discovery Engine (TDE™), the company aims to identify, validate and optimize new targets in the immune response pathway. NextCure’s research platform integrates large‐scale proteomics and functional genomics to accelerate the progression of promising therapeutic candidates from early discovery through clinical development.

The company’s pipeline includes multiple product candidates in various stages of preclinical and clinical evaluation.